Closely-held Cannabotech of Israel entered a new strategic partnership with go NXT LVL of California to develop and manufacturing Cannabotech’s oncology products at go NXT LVL’s facilities in accordance with the California Medical Cannabis Regulations.
Cannabotech expects sales of its products to oncologists and integrative caregivers to start in the fourth quarter of 2022 in California.
Cannabotech also intends to make the scientific information it has accumulated accessible to Californian physicians and caregivers, including research it is currently conducting in Israel on the nine products designed to help patients with breast cancer, colon cancer, pancreatic cancer, lung cancer, prostate cancer and chemotherapy side effects, such as neuropathic and inflammatory pain.
Go NXT LVL has licenses for the production and distribution of medical cannabis products, with production and distribution facilities in Desert Hot Springs, an area exempt from municipal cannabis taxes.
In addition, go NXT LVL has a distribution network for medical cannabis products that advises patients, provides them with medical prescriptions, and delivers products to their homes. Cannabotech plans to use this distribution network as part of its California market penetration strategy.
Following the launch of its products in California, Cannabotech also hope to bring its products to market in the UK and Israel.
“This is a significant milestone in Cannabotech’s growth, allowing us entry into the world’s largest cannabis market, with unique medical solutions that will be specific and distinct from all other players in this arena,” Elhanan Shaked, CEO of Cannabotech, said in a statement.
